US 12,440,562 B2
Method of treating an eye-related disorder by administering an anti-interleukin-4 receptor alpha (anti-IL-4Rα) antibody
Paul Bryce, Bridgewater, NJ (US); Emanuele De Rinaldis, Bridgewater, NJ (US); Ramon Antonio Hernandez Vecino, Paris (FR); Francisco Javier Jimenez Jimenez, Brookline, MA (US); and Cliona Marie Molony, Bridgewater, NJ (US)
Assigned to Sanofi Biotechnology, Paris (FR)
Filed by Sanofi Biotechnology, Paris (FR)
Filed on Aug. 4, 2023, as Appl. No. 18/365,505.
Application 18/365,505 is a continuation of application No. 17/115,618, filed on Dec. 8, 2020, granted, now 11,723,974.
Claims priority of provisional application 63/028,919, filed on May 22, 2020.
Claims priority of provisional application 62/945,807, filed on Dec. 9, 2019.
Claims priority of application No. 20315281 (EP), filed on Nov. 2, 2020; and application No. 20315450 (EP), filed on Nov. 13, 2020.
Prior Publication US 2023/0364231 A1, Nov. 16, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/522 (2006.01); A61K 31/56 (2006.01); A61K 31/573 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); G06N 20/00 (2019.01)
CPC A61K 39/3955 (2013.01) [A61K 9/0019 (2013.01); A61K 31/137 (2013.01); A61K 31/522 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); C07K 16/2866 (2013.01); G06N 20/00 (2019.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01)] 18 Claims
 
1. A method of treating an eye-related disorder in a subject in need thereof with an anti-interleukin-4 receptor alpha (anti-IL-4Rα) antibody, wherein the eye-related disorder is selected from dry eye, blepharitis, cicatricial pemphigoid, Mooren's corneal ulcer, Vogt-Koyanagi-Harada syndrome, sympathetic opthalmia, phacoanaphylaxis endophthalmitis, or a combination thereof, the method comprising administering a therapeutically effective amount of an anti-IL-4Rα antibody to a subject, wherein the anti-IL-4Rα antibody comprises:
a variable heavy chain CDR1 of SEQ ID NO:1 (GFTFRDYA);
a variable heavy chain CDR2 of SEQ ID NO:2 (ISGSGGNT);
a variable heavy chain CDR3 of SEQ ID NO:3 (AKDRLSITIRPRYYGLDV);
a variable light chain CDR1 of SEQ ID NO:4 (QSLLYSIGYNY);
a variable light chain CDR2 of SEQ ID NO:5 (LGS); and
a variable light chain CDR3 of SEQ ID NO:6 (MQALQTPYT).